- This topic is empty.
-
Posts
-
I had been taking CLA (conjugated linoleic acid) for fat loss and many other benefits and just read that it can cause fat to accumulate in the liver while your abdominal fat decreases. Anyone have more info or experience on this?
@mcs5309 3086 wrote:
I had been taking CLA (conjugated linoleic acid) for fat loss and many other benefits and just read that it can cause fat to accumulate in the liver while your abdominal fat decreases. Anyone have more info or experience on this?
Conjugated Linoleic Acid (CLA) may help induce fat loss.
However, it may also have adverse effects. This includes increased cholesterol, increased insulin resistance (e.g. worsening diabetes), accumulation of fat in the liver, gallstones, etc. etc.
Whether or not this occurs appears to depend on the person and the isomer of CLA that is used. However, adverse effects such as the above need to be considered and monitored.
The adverse effects seem to be related to the development of insulin resistance while on CLA.
Thus, one can monitor for adverse effects by monitoring fasting blood sugar, insulin, lipid profile, and a liver panel (or at least the liver tests portion of the comprehensive metabolic panel). A simpler test would be to monitor fasting blood sugar via a blood glucose monitor.
If insulin resistance occurs, which is then a warning sign for the other adverse effects, then CLA treatment can be stopped or some compensatory treatments may be considered, while treatment continues to be monitored.
For example, some research studies show that adding Gamma Linolenic Acid (GLA) or Fish Oil (particularly DHA) can help reduce the risk for insulin resistance and a fatty liver when added to CLA. Some studies show adding Actos can also reduce insulin resistance and fatty liver when added to CLA (however Actos can promote weight gain, which nullifies the primary reason for using CLA).
In any case, while in treatment, monitoring for adverse effects need to continue to help maintain safety.
- You must be logged in to reply to this topic.